Novartis | NVS - Cash And Equivalent



Novartis reported $6.66B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
AbbVie USD 5.18B 349M Mar/2025
Amgen USD 8.03B 782M Jun/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
Bausch Health Companies USD 1.73B 593M Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Canopy Growth CAD 126.2M 109.89M Jun/2025
Corcept Therapeutics USD 102.74M 12.93M Jun/2025
Drreddys Laboratories INR 9B 7.91B Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
Glaxosmithkline GBP 3.6B 271M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Merck USD 8.01B 622M Jun/2025
Novartis USD 6.66B 410M Jun/2025
Novartis USD 6.66B 4.8B Jun/2025
Pacira USD 300.48M 16.87M Jun/2025
Perrigo USD 454.2M 44.3M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Prestige Brands USD 139.5M 41.62M Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Sanofi 15.36B 7.37B Jun/2025
Sanofi 15.36B 7.92B Jun/2025
Supernus Pharmaceuticals USD 144.71M 28.86M Jun/2025
Zoetis USD 1.44B 286M Jun/2025